Nektar Therapeutics announced on July 29, 2025, that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for their investigational biologic therapy, rezpegaldesleukin, aimed at treating severe-to-very severe alopecia areata in adults and children over 12 years old who weigh at least 40 kilograms. Rezpegaldesleukin targets the interleukin-2 receptor complex to promote the proliferation of regulatory T cells, addressing a significant unmet medical need in this chronic, immune-mediated inflammatory disease. This designation allows for more frequent interactions with the FDA and eligibility for accelerated review processes, with Nektar Therapeutics on schedule to release topline data from their Phase 2b study in December.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。